EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Loser

By TheStreet Wire 06/27/12 - 05:01 PM EDT

Find out if (REGN) is in Cramer's Portfolio.

Regeneron Pharmaceuticals (REGN) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.3%. By the end of trading, Regeneron Pharmaceuticals fell $2.39 (-2.1%) to $113.70 on light volume. Throughout the day, 549,112 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of one million shares. The stock ranged in price between $112.57-$116.52 after having opened the day at $114.93 as compared to the previous trading day's close of $116.09. Other company's within the Health Care sector that declined today were: Omeros Corporation (OMER), down 20%, Osiris Therapeutics (OSIR), down 17.4%, Dynacq Healthcare (DYII), down 12%, and Telik (TELK), down 11.9%.

ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $10.6 billion and is part of the drugs industry. Shares are up 109.4% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and poor profit margins.

You can view the full Regeneron Ratings Report.

On the positive front, Aoxing Pharmaceutical Company (AXN), up 34.9%, Arena Pharmaceuticals (ARNA), up 28.7%, Lincare Holdings (LNCR), up 23.4%, and Nanosphere (NSPH), up 21.5%, were all gainers within the health care sector with Baxter International (BAX) being today's featured health care sector winner.

Use our health care section to find sector-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

Find other investment ideas from our top rated ETFs lists.

For more information on Regeneron Pharmaceuticals Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.